In Reply
- PMID: 32918787
- PMCID: PMC8186402
- DOI: 10.1002/ONCO.13518
In Reply
Abstract
This letter to the editor responds to questions about the results of the authors’ recently reported study of chemotherapy in inflammatory myofibroblastic tumors.
Comment on
-
The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.Oncologist. 2020 Nov;25(11):e1777-e1784. doi: 10.1634/theoncologist.2020-0352. Epub 2020 Jul 12. Oncologist. 2020. PMID: 32584482 Free PMC article.
-
Regarding "The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors".Oncologist. 2020 Dec;25(12):e2017. doi: 10.1002/ONCO.13517. Epub 2020 Sep 18. Oncologist. 2020. PMID: 32918748 Free PMC article.
References
-
- Shöffski P, Sufliarsky J, Gelderblom H et al. Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumors with and without anaplastic lymphoma kinase gene alterations (European Organization for Research and Treatment of Cancer 90101 CREATE): A multicentre, single‐drug, prospective, non‐randomized phase 2 trial. Lancet Respir Med 2018;6:431–441. - PubMed
-
- Dalton BG, Thomas PG, Sharp N et al. Inflammatory myofibroblastic tumors in children. J Pediatr Surg 2016;51:541–544. - PubMed
-
- Alaggio R, Cecchetto G, Bisogno G et al. Inflammatory myofibroblastic tumours in childhood: A report from the Italian Cooperative Group studies. Cancer 2010;116:216–226. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
